Roberts Wealth Advisors LLC Purchases 8,739 Shares of Danaher Corporation $DHR

Posted by Geri Gentry on Oct 14th, 2026

Roberts Wealth Advisors LLC purchased a new stake in shares of Danaher Corporation (NYSE:DHR – Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 8,739 shares of the conglomerate’s stock, valued at approximately $1,936,000.

A number of other hedge funds and other institutional investors have also modified their holdings of DHR. BlackRock Inc. acquired a new stake in Danaher in the second quarter worth about $10,492,520,000. Jupiter Topco LLC bought a new position in Danaher in the 2nd quarter valued at about $1,456,317,000. Generation Investment Management LLP acquired a new position in Danaher during the 2nd quarter valued at about $1,287,949,000. Bank of America Corp DE bought a new stake in shares of Danaher during the 2nd quarter worth about $993,846,000. Finally, Legal & General Group Plc bought a new stake in shares of Danaher during the 2nd quarter worth about $801,056,000. 79.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Evercore reaffirmed an “outperform” rating and issued a $230.00 price target on shares of Danaher in a research note on Monday, July 6th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $240.00 price objective on shares of Danaher in a report on Wednesday, July 22nd. UBS Group assumed coverage on shares of Danaher in a research note on Wednesday, September 9th. They set a “buy” rating and a $250.00 price objective on the stock. Wells Fargo & Company dropped their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 22nd. Finally, Morgan Stanley boosted their target price on Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $235.41.

Read Our Latest Stock Report on DHR

Danaher Trading Up 0.9%

Shares of Danaher stock opened at $223.30 on Wednesday. The business has a fifty day simple moving average of $212.41 and a 200-day simple moving average of $195.13. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The firm has a market cap of $156.98 billion, a price-to-earnings ratio of 39.66, a price-to-earnings-growth ratio of 2.78 and a beta of 0.76. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48.

Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The firm had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. Danaher’s revenue was up 5.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.77 earnings per share. On average, equities analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s dividend payout ratio (DPR) is 28.42%.

About Danaher

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.